Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Bayer Seeks EMA Approval for Rivaroxaban

January 5, 2011 6:05 am | News | Comments

Bayer AG says it has submitted an application seeking authorization to sell its new anti-clotting drug Rivaroxaban within the European Union. The company said it is seeking approval from the European Medicines Agency to sell the blood thinner to prevent strokes.


Alabama Prepping for Chantix Lawsuits

January 5, 2011 6:02 am | News | Comments

A federal judge in Birmingham is overseeing at least 1,200 lawsuits involving Pfizer Inc. and its stop-smoking drug Chantix. Many of the lawsuits from smokers and their families claim the drug left them with a variety of psychological problems.


Aclidinium Successfully Treats COPD Symptoms

January 5, 2011 5:59 am | News | Comments

Forest Laboratories Inc. and Almirall SA said that their chronic lung disease drug aclidinium met its main goal in its third late stage clinical trial. The companies said the drug was more effective than placebo at treating chronic obstructive pulmonary disease.


FDA Number Two Leaving the Agency

January 5, 2011 5:55 am | by Brian Witte | News | Comments

Joshua Sharfstein, the Food and Drug Administration's number two official, is leaving the Obama administration and returning to Maryland to become the state's top health official there as Republicans take control of the U.S. House of Representatives.


Primary Corneal Epithelial Cells

January 4, 2011 7:21 am | Product Releases | Comments

ATCC now offers normal human primary corneal epithelial cells. This important cell type is a perfect alternative test method platform for toxicological assays, and can also be used in research related to gene regulation, tissue development, and drug development.


Animal-free Media

January 4, 2011 7:16 am | Product Releases | Comments

Essential Pharmaceuticals, LLC announced that the company will commence sales and distribution of three distinct animal-component-free products: serum replacement, cryopreservation and clinical pathology media.


Burrill & Company Releases 2010 Roundup

January 4, 2011 7:08 am | News | Comments

The biotech industry closed out the year on a high with the Burrill Biotech Select Index surging 4.5 percent in December and end the year up almost 17 percent.


CRA Opens Two New Offices

January 4, 2011 6:57 am | News | Comments

Clinical Research Advantage, Inc., a provider of a range of research services to pharmaceutical companies and clinical research organizations, announced its expansion into the Colorado Springs market with the opening of two local area offices.


Selective Vaccination May Be Effective Against Flu

January 4, 2011 6:48 am | News | Comments

Three physicists have developed an unconventional, theoretical strategy for intensive but limited vaccination against infectious diseases that would replace the practice of mass inoculation over a prolonged period.


Peptide Hurts Breast Cancer In Two Ways

January 4, 2011 6:45 am | News | Comments

Researchers have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice.


Santaris And Pfizer Developing LNA Drug Platform

January 4, 2011 6:40 am | News | Comments

Santaris Pharma A/S and Pfizer Inc. announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid Drug Platform.


Kiadis Teaming with Hospira for ATIR

January 4, 2011 6:32 am | News | Comments

Kiadis Pharma announced that it has entered into a licensing agreement with Hospira, Inc., a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma’s ATIR.


AdvaMed Lobbying Costs 40% Less in 3Q of 2010

January 4, 2011 6:23 am | News | Comments

The medical device industry's chief advocacy group spent over $358,000 lobbying the federal government in the third quarter of 2010, according to a recent disclosure form.


Allergan Spent $250,000 Lobbying in the 3Q

January 4, 2011 6:19 am | News | Comments

Specialty drugmaker Allergan Inc., which makes eye care products and Botox anti-wrinkle injections, spent $250,000 lobbying in the third quarter, according to a federal filing.


New Therapeutic Target for Hepatitis C

January 4, 2011 6:15 am | News | Comments

Scientists have identified a molecular interaction between a structural hepatitis C virus protein and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.